These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15117570)

  • 1. A comparative trial of the safety and efficacy of 0.1 percent pemirolast potassium ophthalmic solution dosed twice or four times a day in patients with seasonal allergic conjunctivitis.
    Gous P; Ropo A
    J Ocul Pharmacol Ther; 2004 Apr; 20(2):139-50. PubMed ID: 15117570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemirolast potassium 0.1% ophthalmic solution is an effective treatment for allergic conjunctivitis: a pooled analysis of two prospective, randomized, double-masked, placebo-controlled, phase III studies.
    Abelson MB; Berdy GJ; Mundorf T; Amdahl LD; Graves AL;
    J Ocul Pharmacol Ther; 2002 Oct; 18(5):475-88. PubMed ID: 12419098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitis.
    Miyake-Kashima M; Takano Y; Tanaka M; Satake Y; Kawakita T; Dogru M; Asano-Kato N; Fukagawa K; Fujishima H
    Jpn J Ophthalmol; 2004; 48(6):587-90. PubMed ID: 15592786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two mast cell stabilizers, pemirolast potassium 0.1% and nedocromil sodium 2%, in the treatment of seasonal allergic conjunctivitis: a comparative study.
    Shulman DG
    Adv Ther; 2003; 20(1):31-40. PubMed ID: 12772816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial.
    Carr WW; Nayak AS; Ratner PH; Gow JA; McNamara TR; Williams JI;
    Allergy Asthma Proc; 2013; 34(3):247-54. PubMed ID: 23484763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis.
    Macejko TT; Bergmann MT; Williams JI; Gow JA; Gomes PJ; McNamara TR; Abelson MB;
    Am J Ophthalmol; 2010 Jul; 150(1):122-127.e5. PubMed ID: 20488431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A 10-week safety and efficacy evaluation of olopatadine, 0.2% instilled twice-daily in patients with allergic conjunctivitis in Japan].
    Ohno S; Ando M
    Nippon Ganka Gakkai Zasshi; 2012 Sep; 116(9):869-79. PubMed ID: 23092094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of preservative-free ketotifen fumarate and preserved olopatadine hydrochloride eye drops in the treatment of moderate to severe seasonal allergic conjunctivitis.
    Mortemousque B; Bourcier T; Khairallah M; Messaoud R; Brignole-Baudouin F; Renault D; Rebika H; Brémond-Gignac D;
    J Fr Ophtalmol; 2014 Jan; 37(1):1-8. PubMed ID: 24388379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a combined therapy with a histamine H1 antagonist and a chemical mediator release inhibitor on allergic conjunctivitis.
    Fujishima H; Fukagawa K; Tanaka M; Uchio E; Takamura E; Nakagawa Y; Miyazaki D; Fukushima A; Okamoto S; Yokoi N
    Ophthalmologica; 2008; 222(4):232-9. PubMed ID: 18463425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemirolast, a new oral nonbronchodilator drug for chronic asthma.
    Kemp JP; Bernstein IL; Bierman CW; Li JT; Siegel SC; Spangenberg RD; Tinkelman DG
    Ann Allergy; 1992 Jun; 68(6):488-91. PubMed ID: 1610024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined analysis of two studies assessing the ocular comfort of antiallergy ophthalmic agents.
    Shulman DG; Amdahl L; Washington C; Graves A
    Clin Ther; 2003 Apr; 25(4):1096-106. PubMed ID: 12809959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms.
    Lanier BQ; Gross RD; Marks BB; Cockrum PC; Juniper EF
    Ann Allergy Asthma Immunol; 2001 Jun; 86(6):641-8. PubMed ID: 11428736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Suppression of conjunctival provocation by 0.1% pemirolast potassium ophthalmic solution in VKC].
    Nakagawa Y; Jikuhara Y; Higasida M; Yuasa T
    Arerugi; 1994 Dec; 43(12):1405-8. PubMed ID: 7535044
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial.
    Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS
    Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of pemirolast in patients with seasonal allergic rhinitis.
    Tinkelman DG; Berkowitz RB
    Ann Allergy; 1991 Feb; 66(2):162-5. PubMed ID: 1994787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nedocromil sodium 2% ophthalmic solution for the treatment of ragweed pollen seasonal allergic conjunctivitis.
    Blumenthal MN; Schwartz RH; Kaiser H
    Ocul Immunol Inflamm; 2000 Sep; 8(3):159-67. PubMed ID: 11120577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol Allergic Conjunctivitis Study Group.
    Dell SJ; Shulman DG; Lowry GM; Howes J
    Am J Ophthalmol; 1997 Jun; 123(6):791-7. PubMed ID: 9535623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.